Actively Recruiting
Comparison Between Interleukin 6 and Procalcitonin in Detecting Sepsis and Mortality in Burn ICU Patients
Led by Ain Shams University · Updated on 2025-04-08
70
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating whether Interleukin-6 (IL-6) is a better indicator than procalcitonin for detecting sepsis or septic shock in burn patients. The study focuses on patients admitted to the burn intensive care unit (ICU) with acute burns, aiming to assess treatment success and early ICU discharge. This research is sponsored by Ain Shams University and involves adult patients between 25 and 60 years old with moderate burns. All participants will have blood samples taken to measure IL-6 and procalcitonin levels on days 1, 3, 7, and 10 after ICU admission. Treatment will follow the standard burn ICU protocol, and the levels of IL-6 and procalcitonin will guide clinical decisions about patient improvement and ICU stays. The study does not use blinding or placebo controls. Participants will be monitored for signs of sepsis and septic shock from day 1 to day 10 in the burn ICU. Researchers will also track the length of ICU stay for up to one month after admission. The study includes regular lab testing and clinical assessments to measure outcomes and guide treatment. The total participation time will vary based on ICU stay and follow-up care.
CONDITIONS
Brief Title
Comparison Between Interleukin 6 and Procalcitonin in Detecting Sepsis and Incidence of Mortality in Burn ICU Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with acute burn admitted to burn ICU within 24 hours from the burn incidence
- Patients with burn percentage of 25% to 50% of total body surface area
- Patients with second to third degree burns
- ASA 1 and ASA 2 patients
You will not qualify if you...
- Burn percentage more than 50% or less than 25% of total body surface area
- Having autoimmune diseases
- Cancer patients
- ASA 3 and ASA 4 patients
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - Up to 24 hours post burn incidence
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 10 days
Participants receive treatment according to the burn ICU protocol. Interleukin 6 and procalcitonin levels are sampled to guide clinical decisions regarding improvement and ICU stay.
4 visits on days 1, 3, 7, and 10 (in-person)
Duration - Up to 1 month after ICU admission
Participants are observed for length of ICU stay and overall clinical outcomes up to one month after ICU admission.
Visits as per routine ICU care
Trial Site Locations
Total: 1 location
1
Ain Shams University
Cairo, Egypt
Actively Recruiting
Research Team
A
Ahmed H Elsayed, M.B.B.CH
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here